Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.39 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953013 | 0.89 | TDP1 (0.45) | TDP1NPC1ALDH1A1POLBHTT | |
| SCHEMBL5952204 | 0.86 | NPC1 (0.42) | NPC1POLBRPS6KA5KDM4EHSD17B10 | |
| SCHEMBL5951634 | 0.82 | PTGDR2 (0.41) | TDP1NPC1POLBKDM4EHSD17B10 | |
| SCHEMBL5953265 | 0.82 | KDM4E (0.55) | NPC1ALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL5952355 | 0.81 | MAPT (0.40) | TDP1NPC1ALDH1A1POLBHTT | |
| SCHEMBL23497756 | 0.79 | TDP1 (0.46) | TDP1NPC1ALDH1A1POLBHTT | |
| SCHEMBL5951878 | 0.77 | NPC1 (0.36) | TDP1NPC1POLBHTTMTNR1A | |
| SCHEMBL5951467 | 0.76 | NPC1 (0.41) | NPC1KDM4E | |
| SCHEMBL1543013 | 0.76 | TDP1 (0.45) | TDP1NPC1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL23497532 | 0.76 | TDP1 (0.43) | TDP1ALDH1A1POLBHTTMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | TDP1 2680/4885NPC1 3302/4885ALDH1A1 1389/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | TDP1 1498/4885NPC1 2551/4885ALDH1A1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.